AVEG 017

A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) February 14, 1994
UBI HIV-1 Peptide Immunogen, Multivalent Env eight branched peptides derived from V3 loop of gp120
UBI HIV-1 Peptide Vaccine, Microparticulate Monovalent Protein
USA 28